Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 7/20 | 0.71 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.71 |
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | TACR3 | P29371 | 6/20 | 0.56 |
| ▸ | TACR2 | P21452 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.51 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8792622 | 0.97 | DHODH (0.72) | DHODHPDE10ALMNATSHRCYP2D6 | |
| SCHEMBL6826836 | 0.89 | DHODH (0.73) | DHODHPDE10ALMNATSHRCYP2D6 | |
| SCHEMBL8793224 | 0.89 | DHODH (0.58) | DHODHPDE10ALMNATSHRCYP2D6 | |
| SCHEMBL619836 | 0.88 | DHODH (0.64) | DHODHPDE10ALMNATSHRCYP2D6 | |
| SCHEMBL8794131 | 0.87 | DHODH (0.76) | DHODHPDE10ALMNATSHRCYP2D6 | |
| SCHEMBL4666226 | 0.85 | DHODH (0.68) | DHODHPDE10ALMNATSHRTACR3 | |
| SCHEMBL8792497 | 0.84 | DHODH (0.60) | DHODHPDE10ALMNATSHRTACR3 | |
| SCHEMBL24122754 | 0.83 | LMNA (1.00) | DHODHPDE10ALMNATSHRCYP2D6 | |
| Oxycinchophen SCHEMBL1170683 | 0.83 | DHODH (1.00) | DHODHPDE10ALMNATSHRCYP2D6 | |
| Oxycinchophen SCHEMBL31654029 | 0.83 | DHODH (1.00) | DHODHPDE10ALMNATSHRCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280949-A1 | Oxopyridyl Quinoline Amides as Nk3 Receptor Modulators | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | US | claimed |
| CN-101287723-A | Amidoalkylpyridylquinolines as NK3 receptor modulators | ASTRAZENECA AB (SE) | 2008-10-15 | — | — | CN | claimed |
| CN-101282964-A | Oxopyridyl quinoline amides as NK3 receptor modulators | ASTRAZENECA AB (SE) | 2008-10-08 | — | — | CN | claimed |
| US-20080200504-A1 | non-peptide NK-3 receptor ligands; anxiety, depression, schizophrenia, obesity; 2-Phenyl-quinoline-4-carboxylic acid (1-pyridin-4-yl-propyl) amide; reacting the 2-phenyl-quinolinyl-4-carbonyl chloride with a pyridylalkylamine to form the amide | ASTRAZENECA AB (SE) | 2008-08-21 | — | — | US | claimed |
| EP-1915362-A1 | AMIDE ALKYL PYRIDIYL QUINOLINES AS NK3 RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2008-04-30 | — | — | EP | claimed |
| EP-1915363-A1 | OXOPYRIDYL QUINOLINE AMIDES AS NK3 RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2008-04-30 | — | — | EP | claimed |
| WO-2007018465-A1 | AMIDE ALKYL PYRIDIYL QUINOLINES AS NK3 RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | WO | claimed |
| WO-2007018469-A1 | OXOPYRIDYL QUINOLINE AMIDES AS NK3 RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | WO | claimed |
| EP-1776343-B1 | QUINOLINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (GB) | 2009-03-04 | — | — | EP | disclosed |
| EP-1776343-B1 | QUINOLINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (GB) | 2009-03-04 | — | — | EP | disclosed |
| US-7482458-B2 | Quinoline derivatives | SMITHKLINE BEECHAM FARMACEUTICA S.P.A. (IT) | 2009-01-27 | — | — | US | disclosed |
| US-7482458-B2 | Quinoline derivatives | SMITHKLINE BEECHAM FARMACEUTICA S.P.A. (IT) | 2009-01-27 | — | — | US | disclosed |
| US-7482458-B2 | Quinoline derivatives | SMITHKLINE BEECHAM FARMACEUTICA S.P.A. (IT) | 2009-01-27 | — | — | US | disclosed |
| US-20080312274-A1 | Quinoline Derivatives as Neurokinin Receptor Antagonists | CARLING WILLIAM ROBERT | 2008-12-18 | — | — | US | disclosed |
| WO-1997021680-A9 | QUINOLINE DERIVATIVES | — | 1997-09-12 | — | — | WO | disclosed |
| CN-1156451-A | Use as tachykinin NK3Quinoline derivatives of receptor antagonists | SMITHKLINE BEECHAM FARMA (IT) | 1997-08-06 | — | — | CN | disclosed |
| WO-1997021680-A1 | QUINOLINE DERIVATIVES | SMITHKLINE BEECHAM S.P.A. (IT) | 1997-06-19 | — | — | WO | disclosed |
| WO-1997019926-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS NEUROKININ 3 (NK-3)- AND NEUROKININ 2 (NK-2) RECEPTOR ANTAGONISTS. | SMITHKLINE BEECHAM S.P.A. (IT) | 1997-06-05 | — | — | WO | disclosed |
| WO-1997019927-A1 | QUINOLINE DERIVATIVES AS NK3 ANTAGONISTS | SMITHKLINE BEECHAM S.P.A. (IT) | 1997-06-05 | — | — | WO | disclosed |
| WO-1995032948-A1 | QUINOLINE DERIVATIVES AS TACHYKININ NK3 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM FARMACEUTICI S.P.A. (IT) | 1995-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312274-A1 | Quinoline Derivatives as Neurokinin Receptor Antagonists | TACR2, TACR3, TACR1 | DHODH 3577/4885PDE10A 2357/4885LMNA 3957/4885 |
| US-20080280949-A1 | Oxopyridyl Quinoline Amides as Nk3 Receptor Modulators | KCNA3, KCNQ3, GPR3 | DHODH 2547/4885PDE10A 2448/4885LMNA 3842/4885 |
| US-20080200504-A1 | non-peptide NK-3 receptor ligands; anxiety, depression, schizophrenia, obesity; 2-Phenyl-quinoline-4-carboxylic acid (1-pyridin-4-yl-propyl) amide; reacting the 2-phenyl-quinolinyl-4-carbonyl chloride with a pyridylalkylamine to form the amide | NPY4R, PROKR1, NPSR1 | DHODH 4351/4885PDE10A 3503/4885LMNA 2776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.